Lisniopril is a blood-pressure lowering drug that belongs to a class of medications called Angiotensin-Converting Enzyme inhibitors or ACEi. Carvedilol belongs to a class of blood pressure lowering medications called beta-blockers that are used for the treatment of high blood pressure, especially in patients with coronary heart disease. Diabetics are known to be at increased risk of coronary artery disease (disease affecting the vessels supplying blood to the heart). Controlled-release carvedilol (Carvedilol CR) is approved by the FDA. In this study, clinical trial formulation of controlled-release carvedilol will be used.